The concern of generic competition has repeatedly loomed over copyright’s blockbuster drug, Viagra, raising questions about the prospects of related pharmaceutical holdings. While early years saw significant returns, the patent lapse has opened the way for cheaper copies, likely lowering earnings and presenting a significant risk for shareholders